MedWatch

FDA accepts ALK’s allergy application

FDA has agreed to review a registration application for a new oral ragweed allergy vaccine submitted by Danish company ALK-Abello and commercial partner Merck.

Foto: Carsten Bundgaard

One of the next great sources of income for Danish allergy group ALK-Abello has moved to the next level, as US partner Merck last week learned that FDA has agreed to review the registration application for ragweed AIT.

Merck submitted the application to the FDA in March 2013, but it is not the only application for new medicine from ALK sitting on FDA’s desk at the moment. In March the US authorities also agreed to review an application for s drug marketed as Grazax in Europa.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier